<DOC>
	<DOCNO>NCT02381158</DOCNO>
	<brief_summary>This single-centre , open label study , aim evaluate efficacy beclomethasone dipropionate apply 12 week dose 400 µg twice day ( total dose 800 µg nebulized ) , airway resistance reactance ( measure Rint FOT technique ) child recurrent wheezing , age 2-5 year . In addition , clinic score frequency symptom exacerbation , assess .</brief_summary>
	<brief_title>Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function Preschool Children With Recurrent Wheezing</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Sounds</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Informed subscribed consent procedure Age range : 2 ≤5 year Male female patient Recurrent wheeze affected ( ≥ 4 episode last 12 month ) PAI positive ( least one primary two secondary ) : Primary : 1. one parent asthma 2 . Atopic Dermatitis 3. sensibilisation air allergen Secondary : 1 . Food sensibilization 2. wheezing also infective episode 3. eosinophilia ( &gt; 4 % ) story severe wheeze require hospitalization treatment inhale glucocorticoid previous 4 week oral glucocorticoid previous 8 week structural abnormality lung ( tracheobronchial bronchomalacia , external compression , etc ) Persistent infection aspiration lung disease ( gastroesophageal reflux disease , etc . ) Cystic fibrosis prematurity bronchopulmonary dysplasia Tuberculosis primary ciliary dyskinesia congenital heart disease pulmonary foreign body bronchiectasis Immunodeficit</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Wheezing</keyword>
	<keyword>Children</keyword>
</DOC>